PSTV (Plus Therapeutics Inc) רווחיות מכירות לפי רווח נקי

Plus Therapeutics, Inc. (PSTV) generates stable income based on the long-term patenting of tumor treatment methods. This chart in the GURU.Markets terminal illustrates the revenue profitability level, where the -306.70 indicator determines the metric's value. While targeted radiotherapy minimizes tissue damage, the risk of a cash crunch and the necessity for additional share offerings due to uncertain brain metastasis data negatively impact the company's capitalization.
plustherapeutics.com - פילוחים אנליטיים ומדדי מפתח (PSTV)

For Plus Therapeutics, Inc. (PSTV), the efficiency of radiopharmaceutical development and insurance reimbursements is determined by net profit per unit of revenue. By analyzing sales margins on GURU.Markets, an investor assesses the portion of income remaining after covering all operating expenses. This metric reveals the alignment of profitability with gross margin trends. Any divergence between these indicators signals risks of capital drawdown. Stable growth of this indicator confirms the fundamental resilience of this high-tech business.